Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Venetoclax plus obinutuzumab improves PFS and MRD-negativity in patients with previously untreated CLL and comorbidities

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 14.06.19
Views: 493
Rating:

Dr Kirsten Fischer - Uniklinik Köln, Cologne, Germany

Dr Kirsten Fischer presents results at the 2019 European Hematology Association (EHA) Annual Meeting from the multinational, open-label, phase 3 CLL14 trial.

Fixed-duration venetoclax plus obinutuzumab induced deep, high, and long lasting MRD-negativity rates in previously untreated patients with chronic lymphocytic leukaemia (CLL) and comorbidities, with this translating into improved progression-free survival (PFS).

Related videos

follow us

Immuno-oncology advances in cancer treatment e-learning


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation